Chikungunya Virus Infection Clinical Trial
Official title:
A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)
The goal of this Phase 2 trial is to evaluate the immune response to and safety profile of various doses/formulations/and schedules of administration of PXVX0317 in healthy adults. Primary Objective: To assess the immune response to the vaccine Secondary Objectives: To assess the kinetics of the immune response to different doses/formulations/schedules To assess the persistence of immune responses to different doses/formulations/schedules To assess the effect of a booster dose of the vaccine Safety Objective: To assess local and systemic reactions to the vaccine and to describe the safety profile of the vaccine
The trial will explore 8 formulation/schedule combinations of CHIKV VLP vaccine with or without Alhydrogel adjuvant, and will also explore different dose schedules of Day 1 and 15 or Day 1 and 29 or Day 29 only. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02230163 -
Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins
|
Phase 1/Phase 2 | |
| Completed |
NCT04546724 -
Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults
|
Phase 3 | |
| Terminated |
NCT04455919 -
Yoga for Chronic Chikungunya
|
N/A | |
| Completed |
NCT03631719 -
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
|
||
| Active, not recruiting |
NCT04441905 -
Phase 1 Study of SAR440894 vs Placebo
|
Phase 1 | |
| Completed |
NCT02562482 -
Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults
|
Phase 2 | |
| Completed |
NCT03028441 -
Phase I Trial of Measles Vectored Chikungungya Vaccine
|
Phase 1 | |
| Completed |
NCT03807843 -
Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
|
Phase 2 | |
| Completed |
NCT04909411 -
Consequences of a Maternal-fetal Chikungunya Virus Infection
|
N/A | |
| Completed |
NCT04786444 -
Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults
|
Phase 3 | |
| Completed |
NCT02553369 -
Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection
|
N/A | |
| Recruiting |
NCT06106581 -
A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years
|
Phase 2 | |
| Recruiting |
NCT06007183 -
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
|
Phase 3 | |
| Completed |
NCT03635086 -
Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)
|
Phase 2 | |
| Completed |
NCT02861586 -
Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine
|
Phase 2 | |
| Active, not recruiting |
NCT04838444 -
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)
|
Phase 3 | |
| Recruiting |
NCT06028841 -
A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV)
|
Phase 3 |